Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sucraid for CSID Symptoms in Pediatric Subjects
NCT05480761Phase 4Terminated
- Sponsor
- QOL Medical
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of sacrosidase in congenital sucrase-isomaltase deficiency (CSID), sponsored by QOL Medical. Started Aug 2022; status: terminated.
02
Drugs
sacrosidase
03
Conditions
congenital sucrase-isomaltase deficiency (CSID)
Beyond the preview
Go deeper on NCT05480761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480761.